A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma

Br J Dermatol. 2018 Aug;179(2):528-529. doi: 10.1111/bjd.16499. Epub 2018 May 30.

Authors

A Marchand¹, A Tallet², C Collin², B Cormier³, Y Venel⁴, E Miquelestorena-Standley^{3

5}, L Machet^{1

5}

Affiliations

¹ Department of Dermatology, CHRU Tours, Tours, France.
² Platform of Somatic Tumor Molecular Genetics, CHRU Tours, Tours, France.
³ Pathology, CHRU Tours, Tours, France.
⁴ Nuclear Medicine, CHRU Tours, Tours, France.
⁵ Université de Tours, Tours, France.

PMID: 29494756
DOI: 10.1111/bjd.16499

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
DNA Mutational Analysis
Humans
Imidazoles / pharmacology
Imidazoles / therapeutic use
Lymphatic Metastasis / genetics
Male
Melanoma / drug therapy*
Melanoma / genetics
Melanoma / pathology
Mutation
Oximes / pharmacology
Oximes / therapeutic use
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / genetics*
Pyridones / pharmacology
Pyridones / therapeutic use
Pyrimidinones / pharmacology
Pyrimidinones / therapeutic use
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics
Skin Neoplasms / pathology
Treatment Outcome

Substances

Imidazoles
Oximes
Pyridones
Pyrimidinones
trametinib
BRAF protein, human
Proto-Oncogene Proteins B-raf
dabrafenib